secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0001493152-23-031993
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LCTX shareholders approve share increase and equity plan amendment at annual meeting
--------------------------------------------------------------------------------

- Authorized common shares increased from 250M to 450M via articles amendment.
- Equity incentive plan share pool increased by 19.5M shares (to 2021 Plan).
- All nine director nominees elected; Angus C. Russell received ~19.6M withheld votes.
- Ratification of WithumSmithBrown as auditor for FY2023 approved (118.5M for).
- Advisory say-on-pay approved with 70.3M votes for; future votes every year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315223031993/0001493152-23-031993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315223031993/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-031993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer